ALPMY Overview
Upcoming Projects (ALPMY)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (ALPMY)
-
Discussing the potential of EO-3021, a Claudin 18.2 ADC), and the Phase I trial in gastric (GC), gastroesophageal junction (GEJ), and pancreatic cancers.
Tickers: ELEV, ALPMY
Executed On: Nov 14, 2024 at 02:00 PM EST -
A Second Look: Discussing the potential of the Optilume Benign Prostatic Hyperplasia Catheter and Balloon system from Urotronic and how it compares to medications from Merck, GSK, and Astellas.
Tickers: UROTRONIC, ALPMY, MRK, GSK
Executed On: Sep 01, 2023 at 08:00 AM EDT -
A Second Look: Discussing the FDA approval of the Revi System, a tibial nerve stimulation system developed by BlueWind Medical for overactive bladder
Tickers: BLUEWIND MEDICAL, ALPMY, MDT, PFE
Executed On: Aug 25, 2023 at 04:00 PM EDT -
Discussing the potential of the Optilume Benign Prostatic Hyperplasia Catheter and Balloon system from Urotronic and how it compares to medications from Merck, GSK, and Astellas.
Tickers: UROTRONIC, ALPMY, MRK, GSK
Executed On: Aug 25, 2023 at 09:00 AM EDT -
Exploring the potential of Iveric's Izervay (avacincaptad pegol intravitreal solution) for patients with Geographic Atrophy after the recent FDA approval
Ticker: ALPMY
Executed On: Aug 11, 2023 at 11:00 AM EDT -
Discussing novel therapeutics to treat gastric cancer/GEJ Adenocarcinoma, including Leap Therapeutics' DKN-01 (anti-DKK1) on top of PD-1 and chemo, as well as Claudin 18.2 (Zolbetuximab from Astellas, & SYSA1801 from Elevation Oncology)
Tickers: LPTX, ELEV, ALPMY
Executed On: Jun 12, 2023 at 01:00 PM EDT -
Examining the potential of Astellas’ fezolinetant as a treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.
Ticker: ALPMY
Executed On: Aug 31, 2022 at 06:00 PM EDT
Upcoming & Overdue Catalysts (ALPMY)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (ALPMY)
-
AstraZeneca and Astellas working with FibroGen in studies treating CKD anemia, with NDA expected in 2018
Tickers: FGEN, AZN, ALPMY
Occurred on: Oct 01, 2018 -
Cytokinetics Announces Start of Phase 1b Clinical Trial of CK-2127107 in Elderly Subjects With Limited Mobility
Tickers: CYTK, ALPMY
Occurred on: Jun 29, 2017 -
Astellas (ALPMY) and Ironwood (IRWD) Expect to Launch Linzess in Japan for the Treatment of Adults with IBS-C in the First Half of 2017
Tickers: IRWD, ALPMY
Occurred on: May 08, 2017 -
Amgen (AMGN) and Astellas Pharma (ALPMY) File Marketing Application in Japan for Romosozumab in Osteoporosis Patients at High Risk of Fracture
Tickers: AMGN, ALPMY
Occurred on: Dec 19, 2016 -
Medivation and Astellas Initiate Phase III Trial of Enzalutamide in Patients With Triple-Negative Breast Cancer
Tickers: MDVN, ALPMY
Occurred on: Jun 02, 2016 -
Phase 2 TERRAIN Trial of enzalutamide Compared to bicalutamide in Metastatic Castration-Resistant Prostate Cancer achieved its primary endpoint
Tickers: MDVN, TSE:4503, ALPMY
Occurred on: Jan 13, 2016
Strategic Initiatives (ALPMY)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
